Increased glycine contributes to synaptic dysfunction and early mortality in Nprl2 seizure model
Brianne Dentel,
Lidiette Angeles-Perez,
Chongyu Ren,
Vikram Jakkamsetti,
Andrew J. Holley,
Daniel Caballero,
Emily Oh,
Jay Gibson,
Juan M. Pascual,
Kimberly M. Huber,
Benjamin P. Tu,
Peter T. Tsai
Affiliations
Brianne Dentel
Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75235, USA
Lidiette Angeles-Perez
Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75235, USA
Chongyu Ren
Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75235, USA
Vikram Jakkamsetti
Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75235, USA
Andrew J. Holley
Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX 75235, USA
Daniel Caballero
Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75235, USA
Emily Oh
Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75235, USA
Jay Gibson
Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX 75235, USA
Juan M. Pascual
Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75235, USA
Kimberly M. Huber
Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX 75235, USA
Benjamin P. Tu
Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX 75235, USA
Peter T. Tsai
Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75235, USA; Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX 75235, USA; Departments of Pediatrics and Psychiatry, UT Southwestern Medical Center, Dallas, TX 75235, USA; Corresponding author
Summary: Targeted therapies for epilepsies associated with the mTORC1 signaling negative regulator GATOR1 are lacking. NPRL2 is a subunit of the GATOR1 complex and mutations in GATOR1 subunits, including NPRL2, are associated with epilepsy. To delineate the mechanisms underlying NPRL2-related epilepsies, we created a mouse (Mus musculus) model with neocortical loss of Nprl2. Mutant mice have increased mTORC1 signaling and exhibit spontaneous seizures. They also display abnormal synaptic function characterized by increased evoked and spontaneous EPSC and decreased evoked and spontaneous IPSC frequencies, respectively. Proteomic and metabolomics studies of Nprl2 mutants revealed alterations in known epilepsy-implicated proteins and metabolic pathways, including increases in the neurotransmitter, glycine. Furthermore, glycine actions on the NMDA receptor contribute to the electrophysiological and survival phenotypes of these mice. Taken together, in this neuronal Nprl2 model, we delineate underlying molecular, metabolic, and electrophysiological mechanisms contributing to mTORC1-related epilepsy, providing potential therapeutic targets for epilepsy.